Ronald O.  Perelman net worth and biography

Ronald Perelman Biography and Net Worth

Major Shareholder of vTv Therapeutics

Ronald Perelman is an American businessman and investor who built his fortune through a wide range of holdings. He is the chairman and CEO of MacAndrews & Forbes Incorporated.

Perelman was born in Greensboro, North Carolina in 1943, and he is said to have learned about business from his father, whose board meetings he would attend while in elementary school. He holds a bachelor of science degree in economics and an MBA from the University of Pennsylvania’s Wharton School of Business.

MacAndrews & Forbes invests in companies with interests in consumer products, entertainment, financial services, biotechnology and gaming. 

Perelman holds shares in companies such as Deluxe Entertainment, Revlon, SIGA Technologies, RetailMeNot, Merisant, Scientific Games Corporation, Valassis, Scantron, vTv Therapeutics, and Harland Clarke.

In light of the economic impact of the COVID-19 pandemic and high debt burdens held by some holdings, MacAndrews & Forbes began selling off shares in several companies in 2020, including Scientific Games, Merisant, MAFCO, and its majority stake in AM General. Perelman also sold several significant works of art from his extensive personal collection. 

Bloomberg Billionaires Index estimated that Perelman’s net worth dropped from $19 billion to $4.2 billion in a two-year period.

Outside of his business interests, Perelman is ranked among the top philanthropists in the United States, focusing on women’s health, education and the arts. He established the Revlon/UCLA Women’s Cancer Research Program, the Ronald O. Perelman Heart Institute at New York Presbyterian Hospital, the Ronald O. Perelman Department of Dermatology at New York University Langone Medical Center, and the Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine at Weill Cornell Medical Center.

Perelman serves on numerous boards, including the Apollo Theater, the Museum of Modern Art, the Tribeca Film Institute, the Rock and Roll Hall of Fame Foundation, and Ford's Theater in Washington, D.C. He also signed the Giving Pledge in 2010, designating up to half of his assets for charitable causes after his family and children have been provided for.

Perelman lives in New York City with his fifth wife, Anna Chapman. He is the father of eight children, two with Chapman and six among his previous wives.

What is Ronald O. Perelman's net worth?

The estimated net worth of Ronald O. Perelman is at least $297,609.60 as of September 16th, 2020. Mr. Perelman owns 17,104 shares of vTv Therapeutics stock worth more than $297,610 as of November 17th. This net worth evaluation does not reflect any other investments that Mr. Perelman may own. Learn More about Ronald O. Perelman's net worth.

How do I contact Ronald O. Perelman?

The corporate mailing address for Mr. Perelman and other vTv Therapeutics executives is 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265. vTv Therapeutics can also be reached via phone at (336) 841-0300 and via email at [email protected]. Learn More on Ronald O. Perelman's contact information.

Has Ronald O. Perelman been buying or selling shares of vTv Therapeutics?

Ronald O. Perelman has not been actively trading shares of vTv Therapeutics during the past quarter. Most recently, Ronald O. Perelman sold 2,175 shares of the business's stock in a transaction on Monday, December 20th. The shares were sold at an average price of $46.00, for a transaction totalling $100,050.00. Learn More on Ronald O. Perelman's trading history.

Ronald O. Perelman Insider Trading History at vTv Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/20/2021Sell2,175$46.00$100,050.00View SEC Filing Icon  
12/17/2020Buy15,625$64.00$1,000,000.00View SEC Filing Icon  
12/10/2020Buy15,625$64.00$1,000,000.00View SEC Filing Icon  
11/24/2020Buy15,625$64.00$1,000,000.00View SEC Filing Icon  
5/12/2020Buy15,625$64.00$1,000,000.00View SEC Filing Icon  
2/25/2020Buy31,250$128.00$4,000,000.00
1/28/2020Buy31,250$64.00$2,000,000.00View SEC Filing Icon  
1/7/2020Buy31,250$64.00$2,000,000.00View SEC Filing Icon  
12/18/2019Buy34,246$58.40$1,999,966.40View SEC Filing Icon  
11/26/2019Buy34,246$58.40$1,999,966.40View SEC Filing Icon  
11/12/2019Buy34,246$58.40$1,999,966.40View SEC Filing Icon  
10/24/2019Buy34,246$58.40$1,999,966.40View SEC Filing Icon  
9/27/2019Buy34,246$58.40$1,999,966.40View SEC Filing Icon  
9/18/2019Buy15,151$66.00$999,966.00View SEC Filing Icon  
8/22/2019Buy1,250$55.20$69,000.00View SEC Filing Icon  
8/19/2019Buy3,750$52.40$196,500.00View SEC Filing Icon  
12/26/2017Buy1,250$161.20$201,500.00View SEC Filing Icon  
8/22/2017Buy500$182.80$91,400.00View SEC Filing Icon  
8/16/2017Buy250$198.80$49,700.00View SEC Filing Icon  
8/15/2017Buy1,250$188.80$236,000.00View SEC Filing Icon  
8/11/2017Buy2,125$165.20$351,050.00View SEC Filing Icon  
4/8/2016Buy250$199.60$49,900.00View SEC Filing Icon  
4/5/2016Buy10,000$208.00$2,080,000.00View SEC Filing Icon  
3/24/2016Buy250$225.60$56,400.00View SEC Filing Icon  
2/12/2016Buy250$233.20$58,300.00View SEC Filing Icon  
2/5/2016Buy250$257.20$64,300.00View SEC Filing Icon  
2/4/2016Buy500$242.00$121,000.00View SEC Filing Icon  
1/13/2016Buy375$256.40$96,150.00View SEC Filing Icon  
12/18/2015Buy375$256.00$96,000.00View SEC Filing Icon  
10/2/2015Buy750$250.40$187,800.00View SEC Filing Icon  
9/28/2015Buy1,000$241.60$241,600.00View SEC Filing Icon  
9/22/2015Buy600$272.80$163,680.00View SEC Filing Icon  
See Full Table

Ronald O. Perelman Buying and Selling Activity at vTv Therapeutics

This chart shows Ronald O Perelman's buying and selling at vTv Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

vTv Therapeutics Company Overview

vTv Therapeutics logo
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
Read More

Today's Range

Now: $17.40
Low: $15.83
High: $18.31

50 Day Range

MA: $14.22
Low: $12.93
High: $17.25

2 Week Range

Now: $17.40
Low: $7.38
High: $30.99

Volume

21,464 shs

Average Volume

48,461 shs

Market Capitalization

$52.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63